Changes of Keratometric Value and Ocular Aberration After Treatment of Meibomian Gland Dysfunction

Yonsei University

Overview

Ocular aberration may play a role in determining optical quality. Recently performed study reported that ocular aberration of preocular tear film would be important factor in not only diagnosing the dry eye but also determining the efficacy of treatment. Therefore, in this study, the investigators will aim to prove the improvement of quality of vision via ocular aberration changes indirectly after the proper treatment for moderate and severe meibomian gland dysfunction. Also, the investigators will evaluate the changes of keratometric values after treatment for moderate and severe meibomian gland dysfunction, which could be demonstrated by autokeratometry, IOLMaster, Pentacam, and iTrace.

Study Type

OBSERVATIONAL

Conditions

Moderate and Severe Meibomiang Gland Dysfunction (Stage 3 or Stage 4 Meibomiang Gland Dysfunction)

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: (1) stage 3 or 4 meibomian gland dysfunction Exclusion Criteria: 1. history of previous ocular or intraocular surgery 2. ocular infection, non dry eye ocular inflammation, ocular allergy, autoimmune disease, 3. history of intolerance or hypersensitivity to any component of the study medications, 4. wearing contact lenses during the study period, presence of current punctal occlusion, 5. pregnancy, lactating women, and children. 6. Additionally, patients were excluded if they were using any topical ocular or systemic medication that could be used for the treatment MGD or dry eye, including topical or oral antibiotics, topical cyclosporine A, topical or oral steroids, topical non-steroidal anti-inflammatory drugs, topical ocular allergy medications or artificial tears

Outcomes

Primary Outcomes

Changes of keratometric value and ocular aberration

Time frame: a minimum of four minutes, once or twice dailybefore treatment, after 1 month, and after 2 months of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.